SCHEMBL4716683

SCHEMBL4716683

CC(C)CCCC(C)CCCC(C)CCCC(C)CCOC(=O)Nc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
ALDH1A1 P00352 1/20 0.57
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
RECQL P46063 1/20 0.54
TSHR P16473 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPSR1 Q6W5P4 2/20 0.49
TP53 P04637 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27756497 1.00 LMNA (0.57) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5540368 0.88 LMNA (0.62) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10595749 0.87 LMNA (0.65) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4713770 0.86 BCHE (0.56) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27756507 0.86 BCHE (0.56) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4714319 0.83 EGFR (0.43) LMNAALDH1A1RAB9ASMN1; SMN2NPSR1
SCHEMBL27756500 0.83 EGFR (0.43) LMNAALDH1A1RAB9ASMN1; SMN2NPSR1
SCHEMBL28775429 0.80 PTPN1 (0.62) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4762696 0.80 PTPN1 (0.62) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL14273829 0.80 PTPN1 (0.62) LMNAALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 CN disclosed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 LMNA 4180/4885ALDH1A1 413/4885NPC1 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.